Quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine (MenACWY-TT): a review

Bibliography

• Aplasca-De Los Reyes M, Dimaano E, Macalalad N, et al. The investigational meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults. Hum Vaccine Immunother 2012;8(7):881-7
   PubMed Web of Science ®Google Scholar
• Stephens DS, Greenwood B, Brandtzaeg P. Seminar: epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007;369(2):196-210
   Google Scholar
• Pollard A. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J 2004;23(Suppl):S274-9
   PubMedGoogle Scholar
• Meningococcal Meningitis Fact Sheet N*141. WHO Media Center 2012
   Google Scholar
• World Health Organization. Meningococcal Disease. WHO Report on Global Surveillance of Epidemic-prone 2000
   Google Scholar
• Dinleyici E, Ceyhan M. The dynamic and changing epidemiology of meningococcal disease at the country-based level: the experience in Turkey. Expert Rev Vaccines 2012;11(5):515-18
   PubMed Web of Science ®Google Scholar
• Perrett K, Pollard A. Towards an improved serogroup B Neisseria meningitidis vaccine. Expert Opin Biol Ther 2005;5(12):1611-25
   PubMed Web of Science ®Google Scholar
• Al-Tawfiq JA, Clark TA, Memish ZA. Meningococcal disease: the organism, clinical presentation, and worldwide epidemiology. J Travel Med 2010;17(Suppl):3-8
   PubMed Web of Science ®Google Scholar
• Ceyhan M, Celik M, Demir ET, et al. Acquisition of meningococcal serogroup W-135 Carriage in turkish Hajj pilgrims who had received the quadrivalent meningococcal polysaccharide vaccine. Clin Vaccine Immunol 2013;20(1):66-8
   PubMed Web of Science ®Google Scholar
• Thigpen MC, Whitney CG, Messonnier NE, Zell ER. Bacterial Meningitis in the United States, 1998-2007. N Engl J of Med 2011;364(21):2016-25
   PubMed Web of Science ®Google Scholar
• Cohn A, MacNeil J, Harrison L, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010;50(2):184-91
   PubMed Web of Science ®Google Scholar
• World Health Organization. Meningococcal vaccines: WHO position paper, November 2011. Weekly Epidemiol Record No 47 2011;86:521-40
   PubMedGoogle Scholar
• Harrison L, Trotter C, Ramsay M. Global epidemiology of meningococcal disease. Vaccine 2009;27(S:2):B51-63
   PubMed Web of Science ®Google Scholar
• Harrison OB, Claus H, Jiang Y, et al. Description and nomenclature of Neisseria meningitidis Capsule Locus. Emerg Infect Dis 2013;4):566-73
   PubMed Web of Science ®Google Scholar
• Knuf M, Romain O, Kindler K, et al. Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2–10-year-old children: results of an open, randomised, controlled study. Eur J Pediatr 2013; [Epub ahead of print]
   Web of Science ®Google Scholar
• World Health Organization. Meningococcal meningitis. Immunization, Vaccines and Biologicals. 2012. Available from: http://www.who.int/immunization/topics/meningitis/en/index.html [Last Accessed 16 February 2013]
   Google Scholar
• Broker M, Jacobsson S, Detora L, et al. Increase in meningococcal serogroup Y cases in Europe: a reason for concern. Hum Vaccine Immunother 2012;8(5):685-8
   PubMed Web of Science ®Google Scholar
• Croxtall JD, Dhillon S. Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate VACCINE (Nimenrix). Drugs 2012;72(18):2407-30
   PubMed Web of Science ®Google Scholar
• Stephens D. Conquering the meningococcus. FEMS Microbiol Rev 2007;31(1):3-14
   PubMed Web of Science ®Google Scholar
• Tan L, Carolene G, Borrow R. Advances in the Development of Vaccines against Neisseria meningitidis. N Engl J Med 2010;362(16):1511-20
   PubMed Web of Science ®Google Scholar
• Seward RJ, Towner KJ. Evaluation of a PCR-immunoassay technique for detection of Neisserria menegitidis in cerebrospinal fluid and peripheral blood. J Med Microbiol 2000;49:451-6
   PubMed Web of Science ®Google Scholar
• Vesikari T, Forstén A, Boutriau D, et al. A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2–10 years. Hum Vaccine Immunother 2012;8(10):1-10
   PubMedGoogle Scholar
• Trotter CL, Ramsay ME. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev 2007;31:101-7
   PubMed Web of Science ®Google Scholar
• Carter NJ. Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero®): A review of its use in primary and booster vaccination. BioDrugs 2013; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Campbell H, Borrow R, Salisbury D, Miller E. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine 2009;27(Suppl 2):e20-9
   PubMed Web of Science ®Google Scholar
• Harrison L. Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev 2006;19(1):142-64
   PubMed Web of Science ®Google Scholar
• Dbaibo G, Macalalad N, Aplasca-De Los Reyes M, et al. The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135 Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine A randomized, controlled non-inferiority study. Hum Vaccine Immunother 2012;8(7):873-80
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Assessment report Nimenrix. Procedure N0.EMAE/H/C/002226. 2012. Available from: http://www.ema.europa.edu/docs/enGB/document_library/EPAR_-_Public_assessment_report/human/002226/WC500127664.pdf [Last Accessed 17 February 2013]
   Google Scholar
• Joshi VS, Bajaj IB, Shrikant A. Meningococcal polysaccharide vaccines: a review. Carbohydr Polym 2009;75:553-65
   Web of Science ®Google Scholar
• Heath P, McVernon J. The UK Hib vaccine experience. Arch Dis Child 2002;86(6):396-9
   PubMed Web of Science ®Google Scholar
• Whitney C, Farley M, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003;348(18):1737-46
   PubMed Web of Science ®Google Scholar
• Maiden M, Stuart J; UK Meningococcal Carriage Group. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002;359(9320):1829-31
   PubMed Web of Science ®Google Scholar
• Ramsay M, Andrews N, Trotter C, et al. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003;326(7385):365-6
   PubMed Web of Science ®Google Scholar
• Papaevangelou V, Spyridis N. MenACWY-TT vaccine for active immunization against invasive meningococcal disease. Expert Rev Vaccines 2012;11(5):523-37
   PubMed Web of Science ®Google Scholar
• Girard M, Preziosi M, Aguado M, Kieny M. A review of vaccine research and development: meningococcal disease. Vaccine 2006;24(22):4692-700
   PubMed Web of Science ®Google Scholar
• Pace D, Pollard AJ, Messonier NE. Quadrivalent meningococcal conjugate vaccines. Vaccine 2009;27(Suppl 2):B30-41
   PubMedGoogle Scholar
• Center for Disease Control and Prevention. Infant meningococcal vaccination: advisory committee on immunization practices (ACIP) recommendations and rationale. Center for Disease Control and Prevention. MMWR 2013;62(3):41-60
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Infant meningococcal vaccination: advisory committee on immunization practices (ACIP) recommendations and rationale. MMWR 2012;62(03):52-4
   Google Scholar
• GlaxoSmithKline, Inc. GlaxoSmithKline receives European authorisation for Nimenrix™ (Meningococcal group A, C, W-135 and Y conjugate vaccine). 2012. Available from: http://www.gsk.com/media/press-releases/2012/glaxosmithkline-receives-european-authorisation-for-nimenrix-meningococcal-group-a-c-w-135-and-y-conjugate-vaccine.html [Last Accessed 17 February 2013]
   Google Scholar
• Miller J, Mesaros N, Van Der Wielen M, Baine Y. Conjugate meningococcal vaccines development: GSK Biologicals experience. Adv Prevent Med 2011;2011:1-17
   Google Scholar
• GlaxoSmithKline, Inc. NIMENRIX™ Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine Product Monograph: GlaxoSmithKline, Inc; 2013
   Google Scholar
• Knuf M, Kieninger-Baum D, Habermehl P, et al. A dose- range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine 2010;28(3):744-53
   PubMed Web of Science ®Google Scholar
• Østergaard L, Lebacq E, Poolman J, et al. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine 2009;27(1):161-8
   PubMed Web of Science ®Google Scholar
• Muthukkumar S, Stein K. Immunization with meningococcal polysaccharide-tetanus toxoid conjugate induces polysaccharide-reactive T cells in mice. Vaccine 2004;22(9-10):1290-9
   PubMed Web of Science ®Google Scholar
• Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection–serum bactericidal antibody activity. Vaccine 2005;23(17-18):2222-7
   PubMed Web of Science ®Google Scholar
• Wu D, Rinaldi F, Huang Y, et al. Economic evaluation of universal 7-valent pneumococcal conjugate vaccination in Taiwan: a cost-effectiveness analysis. J Formos Med Assoc 2013;112(3):151-60
   PubMed Web of Science ®Google Scholar
• Stephens DS. Protecting the herd: the remarkable effectiveness of the bacterial meningitis polysaccharide-protein conjugate vaccines in altering transmission dynamics. Trans Am Clin Climatol Assoc 2011;122:115-23
   PubMedGoogle Scholar
• Campbell H, Andrews N, Borrow R, et al. Updated postlicensure surveillance of the meningococcal c conjugate vaccine in england and wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 2010;17(5):840-7
   PubMed Web of Science ®Google Scholar
• Kristiansen PA, Diomandé F, Ba AK, et al. Impact of the serogroup A meningococcal conjugate vaccine, MenAfrivac, on carriage and herd immunity. Clin Infect Dis 2013;56(3):354-63
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Andrews NJ, Waight P, et al. Impact of the 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in infants younger than 90 days in england and wales. Clin Infect Dis 2013;56(5):633-40
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO Guidelines on Nonclinical Evaluations of Vaccines: WHO Technical Report Series; 2003
   Google Scholar
• Committee for Medical Products for Human Use CHMP. Guideline on clinical evaluation of new vaccines. European Medicines Agency; London, UK: 2006
   Google Scholar
• Bermal N, Huang L, Dubey A, et al. Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults. Hum Vaccin 2011;7(2):239-47
   PubMed Web of Science ®Google Scholar
• Baxter R, Baine Y, Ensor K, Bianco V. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age. Infect Dis J 2011;30:3
   Web of Science ®Google Scholar
• Klein N, Baine Y, Bianco V, et al. One or two doses of quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine is immunogenic in 9-12 month old children. Pediatr Infect Dis J 2013; [Epub ahead of print]
   Web of Science ®Google Scholar
• Borja-Tabora C, Montalban C, Memish ZA, et al. Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study. BMC Infect Dis 2013;13:116
   PubMed Web of Science ®Google Scholar
• Dbaibo G, Van de Wielen M, Reda M, et al. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine. Int J Infect Dis 2012;16:e608-15
   Google Scholar
• Knuf M, Baine Y, Bianco V, et al. Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children. Hum Vaccine Immunother 2012;8(7):866-72
   PubMed Web of Science ®Google Scholar
• Østergaard L, Van der Wielen M, Bianco V, et al. Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus conjugate vaccine(MenACWY-TT). Int J Infect Dis 2013;17(3):e173-e76
   PubMed Web of Science ®Google Scholar
• Vesikari T, Forsten A, Boutriau D, et al. Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers. Hum Vaccin Immunother 2012;8(12):1892-903
   PubMed Web of Science ®Google Scholar
• Memish ZA, Dbaibo G, Montellano M, et al. Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2-to10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile. Pediatr Infect Dis J 2011;30(4):e56-62
   PubMed Web of Science ®Google Scholar
• Dbaibo G, El-Ayoubi N, Ghanem S, et al. Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine MenACWY-TT administered to adults aged 56 years and older: results of an open-label, randomized, control trial. Drugs Aging 2013;30(5):309-19
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Bianco V, et al. Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles–mumps–rubella–varicella vaccine during the second year of life: an open, randomized controlled trial. Vaccine 2011;29(25):4274-84
   PubMed Web of Science ®Google Scholar
• Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U, et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with InfanrixTM hexa is immunogenic, with an acceptable safety profile in 12–23-month-old children. Vaccine 2011;29(25):4264-73
   PubMed Web of Science ®Google Scholar
• Ruiz-Palacios G, Huang L, Lin T, et al. Immunogenicity and safety of a booster dose of the 10 valent pneumococcal Haemophilus influenzae protein D conjugate vaccine coadministered with the tetravalent meningococcal serogroups A,C,W-135 and Y tetanus toxoid conjugate vaccine in toddlers: a randomized trial. Pediatr Infect Dis J 2013;32(1):62-71
   PubMed Web of Science ®Google Scholar
• Østergaard L, Silfverdal S, Berglund J, Flodmark C. A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix® in subjects aged 11–17 years: An open, randomised, controlled trial. Vaccine 2012;30:774-83
   PubMed Web of Science ®Google Scholar
• Black S, Klein N, Shah J, et al. Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age. Vaccine 2010;28:657-63
   PubMed Web of Science ®Google Scholar
• ClinicalTrial.gov. MenACWYTT search. ClinicalTrialsgov: A service of the US National Institutes of Health. Available from: http://www.clinicaltrials.gov/ct2/results?term=GSK134612 [Last Accessed 16 February 2013]
   Google Scholar